This review describes the drug development and mechanism of action of aflibercept (Eylea®), an anti-VEGF agent specifically designed for ophthalmic use. It is indicated in adults with neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of vision impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) and diabetic macular oedema (DME), all indications for which it is fully funded under the Pharmaceutical Benefits Scheme (PBS; authority required). Aflibercept is also indicated for treatment of branch retinal vein occlusion (BRVO) but currently is not funded under the PBS for this indication.
Please login below to download this issue (PDF)